BEST PRACTICES IN:

Recognition and Management of Nighttime Reflux Symptoms

Background

A majority of patients with gastroesophageal reflux disease (GERD) report nighttime symptoms, including heartburn during sleep. Nighttime reflux is associated with more severe forms of GERD.^{1,2} Multiple studies have demonstrated that nighttime GERD has a substantial adverse impact on sleep and quality of life.^{3,4}

Epidemiology

The vast array of effective therapeutic options for GERD—including antacids, histamine-2 receptor antagonists, and proton pump inhibitors (PPIs)—has until recently obscured the impact of nighttime GERD. A survey of 1,000 GERD patients showed that 79% had nocturnal heartburn, and 75% of those said the symptoms affected their sleep.⁵ In another study, Farup and colleagues⁶ found that 74% of patients with frequent GERD symptoms reported nocturnal symptoms and 54% said heartburn awakened them from sleep. In these studies, most GERD patients had symptoms both during the day and during the night; however, of those, most patients found their nighttime symptoms to be more troublesome. Other studies have documented lower, but still substantial, rates of nighttime GERD symptoms. A community-based study found a 47% prevalence of nocturnal heartburn and a 34% prevalence of nocturnal acid regurgitation.⁷ Data from a large prospective cohort study showed that 25% of participants reported heartburn during sleep.8

Characteristics

GERD patients who have symptoms both during the day and at night find nocturnal heartburn more bothersome than daytime symptoms. ^{5,6} This might be explained by physiologic differences between the day, when patients are upright, and the night, when patients are generally recumbent. During wakefulness, acid reflux tends to occur more frequently but has a shorter duration compared to reflux during sleep; nocturnal reflux episodes often last substantially longer. ⁹ In an animal model of esophagitis, prolongation of acid contact with the mucosa was associated with more severe esophageal lesions. ¹⁰

Nocturnal acid breakthrough (NAB) refers to an intragastric pH <4 for at least 1 continuous hour overnight. Initially limited to twice-daily PPI therapy, the definition of NAB has been expanded to include once-daily PPI therapy. 11-13 NAB has been documented in about 70% of healthy volunteers or GERD patients during treatment with a PPI.

Consequences

The presence of nighttime GERD increases the likelihood of various clinical manifestations, such as erosive esophagitis, esophageal stricture, Barrett's esophagus, and esophageal adenocarcinoma. Additionally, patients with nighttime GERD are more likely to experience extraesophageal manifestations, such as laryngitis, aspiration, and asthma. 1,2

Several studies have documented associations between nighttime GERD and sleep disturbance. A nationwide telephone survey of 1,000 GERD patients,⁵ commissioned by the American Gastroenterological Association, showed that 75% of respondents with nighttime GERD reported altered sleep, and 63% said nighttime heartburn negatively affected their ability to sleep. Additionally, 40% of respondents with nocturnal GERD said the condition adversely affected their ability to function the following day. As the frequency of nighttime GERD increased, so did the likelihood of sleep disturbance.

GERD is a common clinical finding in patients with obstructive sleep apnea (OSA). Moreover, people affected by both conditions have significantly poorer quality of life compared to individuals who have OSA alone. ¹⁴



Colin W. Howden, MD Professor, Division of Gastroenterology Northwestern University Feinberg School of Medicine, Chicago

impact on quality of life. Farup and colleagues⁶ found that GERD patients with nocturnal symptoms had significantly greater impairment in quality of life than GERD patients who had only daytime symptoms and compared to healthy controls without GERD. Patients with nocturnal heartburn reported significantly more pain compared to diabetic

Not surprisingly,

given the multitude of

potential clinical mani-

festations, nighttime

GERD has a negative

patients and a similar degree of pain compared to patients with angina pectoris and congestive heart failure.

Risk Factors

Relatively few studies have examined potential risk factors for nighttime GERD. Nighttime consumption of reflux-provoking meals¹⁵ and body position during sleep have been implicated in some studies.¹⁶

Information gleaned from a US database of 15,700 people showed that greater body mass index (BMI) and younger age were associated with an increased risk of GERD.⁴ Men and college-educated individuals were less likely to report nocturnal GERD, whereas Caucasians and Native Americans were more likely to report this condition. Nighttime heartburn also had positive associations with smoking, hypertension, stroke, asthma, and consumption of carbonated soft drinks. Medications associated with heartburn during sleep included antidepressants, calcium-channel blockers, and benzodiazepines.

In multivariate analyses, the factors that maintained significant associations with nocturnal GERD were college education, higher BMI, carbonated drink consumption, snoring, daytime sleepiness, insomnia, hypertension, asthma, and use of benzodiazepines.⁴

Therapeutic Implications

The development of PPIs has had a dramatic impact on GERD management. Nonetheless, conventional delayed-release PPIs achieve incomplete control of nocturnal gastric acid secretion. Adaptive of intragastric pH $\,>4$ throughout the day and night is desirable in order to limit the biological activity of pepsin on the esophageal mucosa; in essence, pepsin is biologically inactive at pH levels $\,>4$. As a result, a reflux episode that occurs when gastric contents are at a pH $\,>4$ will not have a caustic effect on the esophagus. Furthermore, the ability of acid-suppressing drugs to maintain intragastric pH $\,>4$ correlates significantly with their efficacy in healing erosive esophagitis. 18

Delayed-release PPIs have enteric coatings that delay drug absorption into systemic circulation. This results in erratic and unpredictable absorption patterns. Currently, the only PPI without a delayed-release formulation is immediate-release omeprazole (IR-OME) with sodium bicarbonate. When administered as a non-enteric coated capsule or a powder, IR-OME has demonstrated more rapid systemic absorption and a higher mean peak plasma concentration of omeprazole than the conventional enteric-coated/delayed-release formulation of omeprazole.¹⁸

Recently, IR-OME was compared with delayed-release PPIs in two separate studies involving GERD patients with nighttime symptoms. ^{12,13} The first study showed

that IR-OME administered at bedtime produced significantly better control of nocturnal gastric acidity than pantoprazole administered prior to the evening meal. The second study showed that IR-OME dosed at bedtime provided more rapid control of nighttime gastric pH and better control of NAB compared to delayed-release esomeprazole and lansoprazole, also administered at bedtime.

Nonpharmacologic interventions also can aid in the control of nocturnal gastric acidity. Avoidance of carbonated drinks, alcohol, and food for 2 to 3 hours before bedtime can help minimize the chances of nocturnal reflux. Smoking cessation is important for all GERD patients. When indicated, weight loss may also have a beneficial effect on nocturnal GERD symptoms.

References

- Cuttitta G, Cibella F, Visconti A, et al. Spontaneous gastroesophageal reflux and airway patency during the night in adult asthmatics. Am J Respir Crit Care Med. 2000;161:177-181.
- Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with 'reflux laryngitis'. Gastroenterology. 1991;100:305-310.
- Green C, Dekel R, Quan S, et al. The relationship between the extent of esophageal acid exposure and reported quality of sleep. Gastrointest Endosc. 2003;57:AB133. M1749 [Abstract].
- Dekel R, Green C, Quan S, et al. The relationship between severity and frequency of symptoms and quality of sleep in patients with gastroesophageal reflux disease (GERD). Gastroenterology. 2003;124:A414. M2093 [Abstract].
- Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup Survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol. 2003;98:1487-1493.
- Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45-52.
- Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
- 8. Fass R, Quan SF, O'Connor GT, et al. Predictors of heartburn during sleep in a large prospective cohort study. *Chest.* 2005;127:1658-1666.
- Orr WC, Johnson LF, Robinson MG. Effect of sleep on swallowing, esophageal peristalsis, and acid clearance. Gastroenterology. 1984;86:814-819.
- 10. Johnson LF, Harmon JW. Experimental esophagitis in a rabbit model: Clinical relevance. *J Clin Gastroenterol.* 1986;8(suppl 1):26-44.
- Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. *Am J Gastroenterol.* 1998;93:763-767.
- 12. Castell D, Bagin R, Goldlust B, et al. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-esophageal reflux disease. *Aliment Pharmacol Ther.* 2005;21:1467-1474.
- 13. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25:197-205.
- 14. Guda N, Partington S, Vakil N. Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea. Aliment Pharmacol Ther. 2004;20:1153-1159.
- 15. Hila A, Castell DO. Nighttime reflux is primarily an early event. *J Clin Gastroenterol.* 2005;39:579-583.
- Khoury RM, Camacho-Lobato L, Katz PO, et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:2069-2073.
- Howden CW. Review article: Pharmacological approaches to the optimal control of nocturnal intragastric acidity. Aliment Pharmacol Ther. 2006;3:39-45.
- Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. *Digestion*. 1992;51(Suppl 1):59-67.

This supplement was produced by the customized publication department of Elsevier/International Medical News Group. Neither the editor of Internal Medicine News, the Editorial Advisory Board, nor the reporting staff contributed to its content. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter or of the Publisher.

Copyright © 2007 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.